Drug intelligence / Profile preview

m590

Development stage: Preclinical
Lead developer: MacroGenics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

m590 is an anti-IGF-IR monoclonal antibody that has demonstrated the ability to inhibit the proliferation and migration of breast cancer MCF-7 cells in vitro. It targets the type I insulin-like growth factor receptor (IGF-IR) and has shown antitumor activity in preclinical models. This antibody was also utilized in the engineering of a bispecific antibody designed to co-target both HER2 and IGF-IR.

Targets

IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on m590.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on m590.